Market Trends of Germany In-Vitro Diagnostics Industry
The Molecular Diagnostic Segment is Expected to Witness Healthy Growth Over the Forecast Period
- Molecular diagnostics are used to analyze biological markers in the genome and proteome to detect pathogens or mutations. Nucleic acid amplification technology for molecular diagnostics is the gold standard method for detecting viruses and has been increasingly adopted. The market players constantly focus on product launches based on nucleic acid amplification and product development strategies for COVID-19.
- This development is fueled by the introduction of powerful techniques, such as real-time polymerase chain reaction (PCR) and next-generation sequencing (NGS), which allow the amplification and decoding of genetic and epigenetic information.
- Furthermore, the rising awareness initiatives in molecular diagnostic screening are expected to drive the segment growth further. For instance, in May 2021, Seegene Germany GmbH took part in the government's Back-to-School program called the Lolli-Test, a starting point in returning our daily lives to normalcy. Under the program, Seegene Germany GmbH has supplied COVID-19 diagnostic tests to laboratories in business with the federal government, worth up to 19.3 million Euros. Such initiatives have led to increased adoption of molecular diagnostics tests in Germany, driving the market growth.
- Initiatives in strategies such as new product development, collaborations, acquisitions, and funding in research and development are adopted by key players to secure their positions in the German market. For instance, in March 2021, German company ZytoVision GmbH entered into a distribution agreement with Bio SB for the distribution of line ZytoVision of CE-approved chromogenic in situ hybridization and fluorescent in situ hybridization probes targeted for use in lung carcinomas.
- Hence, factors such as rising initiatives from the key market players, such as distribution of products and rising awareness of in-vitro diagnostic testing, are expected to drive the segment growth over the forecast period
Understand The Key Trends Shaping This Market
Download Sample
Cancer/Oncology Among Applications is Expected to Hold a Significant Share in the Market Studied
- The factors driving the growth of the segment include the high burden on cancer, rising initiatives, and a strong foothold of key market players.
- According to the Statistisches Bundesamt (Destatis), in 2023, cancer is the fourth most frequent reason for treatment in Germany, accounting for 8% of all hospital stays with lung and bronchial cancer, particularly in common. Furthermore, according to the same source, in 2021, around 1.44 million patients were treated for cancer in hospitals on an in-patient basis in Germany. Such a huge burden of cancer in Germany is anticipated to drive market growth due to the increased adoption of IVDs for cancers.
- In addition, strategies such as new product development, collaborations, acquisitions, and funding in research and development are adopted by key players to secure their positions in the German market, driving segment growth. For instance, in March 2021, German company ZytoVision GmbH entered into a distribution agreement with Bio SB to distribute line ZytoVision of CE-approved chromogenic in situ hybridization and fluorescent in situ hybridization probes targeted for use in lung carcinomas.
- Hence, owing to the rising burden of cancer and key initiatives such as the distribution of products by market players is expected to drive the segment growth over the forecast period.
